SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

4Chan is trending as community members rally around its scarcity and potential for high returns, touting it as the "bitcoin of memecoins". Despite some volatility, holders express confidence and encourage others to "hodl" for long-term gains. Discussions also revolve around its cultural significance as the origin of many internet memes.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as community members rally behind it as the top memecoin on the Bitcoin network, emphasizing its fair launch and strong community, dubbed the 'DOG Army'. Many see it as a cultural and economic driver for Bitcoin, and holders are anticipating increased attention as the ecosystem around Runes develops. Some community members believe it will outcompete other memecoins like Doge.

This platform is engineered to unlock the full potential of Real-World Assets (RWAs) by bringing them onto the XRP Ledger with unparalleled efficiency. Our purpose is to democratize access to high-value assets by providing a streamlined, end-to-end solution for tokenization. Functionally, we offer tools for asset verification, compliant legal wrapping, and the minting of RWA tokens. The project's core utility is twofold: for asset owners, it unlocks immediate liquidity and access to global capital markets; for investors, it offers fractional, transparent, and liquid access to investment classes like private equity and infrastructure bonds. We leverage the XRPL's native speed and built-in DEX to ensure low-cost transactions and instant settlement, setting a new standard for RWA interoperability and finance.

VOLT

XVM.X is trending as community members discuss its potential as a real-world asset (RWA) coin, drawing comparisons to XRP. Recent price appreciation and ease of access on platforms like Phantom are also being highlighted, with many believing it's still early to get in. Some users are also mentioning a connection to GoMining, a platform for virtual Bitcoin mining.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu ($SHI.X) is trending as community members highlight its bullish chart patterns, coiling action, and potential for a breakout. Despite some negative sentiment, many believe $SHI.X possesses meme power and offers significant upside, with some drawing comparisons to Shiba Inu ($SHIB.X). The community also notes the project's tokenomics and potential for long-term growth.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin's stock is trending due to its impending inclusion in the S&P 500, set to take effect on September 22nd, which has sparked significant community discussion. While some debate the company's fundamentals, many believe index inclusion will drive further gains due to increased visibility and automatic investment from index funds, despite some cautioning about potential short-term profit-taking following the official inclusion.

Interactive Brokers Group, Inc. is an investment holding company, which engages in broker or dealer and proprietary trading businesses. It offers custody and service accounts for hedge and mutual funds, exchange-traded funds, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. The company was founded by Thomas Pechy Peterffy in 1977 and is headquartered in Greenwich, CT.

Interactive Brokers Group Inc - Ordinary Shares - Class A

Interactive Brokers Group Inc 

Interactive Brokers is trending amid discussions around a recent price dip, despite strong fundamentals and growth in customer accounts. Community members are debating the reasons behind the stock's performance, including its addition to the S&P 500 and potential market factors like interest rate concerns. Some investors view the dip as a buying opportunity, while others express frustration with the stock's recent action.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

NFLX is trending amid discussions about its content strategy, potential stock split, and comparisons to competitors. Community members are debating its valuation and future growth prospects, with some expressing bullish sentiment and others remaining cautious. The stock's performance relative to broader market trends and potential catalysts like new content releases are also key talking points.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as community members discuss the potential of ivonescimab, particularly following Akeso's report of reaching the OS endpoint. Anticipation is building for the presentation of HARMONi data, with community speculation on a potential deal with AstraZeneca. Discussions also focus on short interest and the possibility of a squeeze.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors discuss the company's communication strategies and the potential impact of recent reports on revenue forecasts. The community is focused on upcoming catalysts, like the CIOE 2025, and eagerly awaits news about purchase orders and partnerships that could drive significant growth. Concerns remain around commercialization timelines and the effectiveness of current investor relations efforts.

Volatility Shares Trust - Volatility Shares Trust XRP ETF

XRP ETF

XRPI is trending as traders discuss its potential correlation with XRP's price movements and the possibility of increased adoption in banking payment systems. Community members are actively analyzing chart patterns, anticipating potential breakouts, and evaluating its suitability for long-term investment within Roth IRAs. The broader context involves speculation around regulatory clarity and the potential impact of partnerships with financial institutions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 0.00% and +14.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy?

Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered into a licensing deal with Biosion for rights for two antibody products and announced an $80 million funding, lifting retail sentiment.Aclaris is focused on developing drugs to treat immuno-inflammatory diseases. The exclusive license agreement with Biosion includes worldwide rights (excluding Greater China) to BSI-045B, a clinical-stage, novel anti-TSLP monoclonal antibody; and BSI-502, a pre-clinical stage novel bispecific antibody directed against “both TSLP and IL4R,” used to treat conditions like atopic dermatitis. &nbsp;The private placement includes over 35.55 million shares of common stock at a purchase price of $2.25 per share. The placement is expected to close on or about Nov. 19, 2024, subject to customary closing conditions.Vivo Capital led the funding, with participation from new and existing investors including Forge Life Science Partners, Rock Springs Capital, RA Capital Management, Adage Capital Partners LP, Decheng Capital, Logos Capital and Samsara BioCapital.Several brokerages have revised their ratings for Aclaris following the news. Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2. The firm cited completion of the company's strategic review, and expects investor focus to shift to its "newly strengthened" immunology-focused pipeline that includes the two in-licensed biologics from discovery-focused Biosion - BSI-045B and BSI-502, The Fly.com <a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/">reported.</a>Jefferies also upgraded Aclaris to ‘Buy’ from ‘Hold’ with a price target of $7, up from $2.Meanwhile, Piper Sandler upgraded the company to ‘Overweight’ from ‘Neutral’ with a price target of $13, up from $3.Retail sentiment moved from ‘neutral’ (47/100) to ‘extremely bullish’(96/100); message volumes rose to ‘extremely high’ levels from ‘normal’.<figure class="image"><img style="aspect-ratio:1304/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_19_at_9_24_37_PM_b73837e53c.png" alt="Screenshot 2024-11-19 at 9.24.37 PM.png" width="1304" height="290"><figcaption>ACRS sentiment and message volumes on Nov 19 as of 10:55 am ET| Source: Stocktwits</figcaption></figure>“This transformative transaction, which marks the completion of our strategic review process, accelerates our evolution into becoming a leading immunology company with both small and large molecule drugs," Neal Walker, interim CEO and chair of Aclaris, said in a statement.Net proceeds from the capital raise are expected to fund the research and development of its drug pipeline and for general corporate purposes.Aclaris stock is up 300% year-to-date.For updates and corrections, email newsroom@stocktwits.com &nbsp;&nbsp;

Net proceeds from the capital raise are expected to fund the research and development of its drug pipeline| Picture source: pexels

Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps

Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2; Piper Sandler upgraded the company  to ‘Overweight’ from ‘Neutral.’ 

Equity

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets Biosion Announces Exclusive, Global License...

H.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Aclaris Therapeutics (ACRS Research Report). The compa...

Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties

Aclaris Therapeutics (ACRS) has provided an update. Aclaris Therapeutics has struck a lucrative deal with OMERS, selling a portion of its future ro...

Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying

Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to Sell at StockNews.com

StockNews.com cut shares of Aclaris Therapeutics (NASDAQ:ACRS - Free Report) from a hold rating to a sell rating in a research note released on Tuesday morning.
Several other brokerages also recently...

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

ACRS
Aclaris Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACRS News

ACRS Aclaris Therapeutics Inc